Research
Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial
The Brief
- ZEUS, a global phase 3 clinical trial, produced neutral findings on an anti-inflammatory approach to heart disease.
- Inflammation causally contributes to cardiovascular disease risk, much like cholesterol does.
- The results suggest that targeting inflammation may be less straightforward than once thought.
Why it matters
Anti-inflammatory treatment was considered a promising route to lowering heart disease risk, so neutral trial results affect how researchers design future prevention studies.
Who’s affected
- Researchers studying cardiovascular disease and inflammation
- #cardiovascular
- #inflammation
- #clinical-trial
- #heart-disease
Like cholesterol, inflammation causally contributes to the risk of cardiovascular disease, but findings from the clinical trial ZEUS indicate that the road to targeting inflammation may be less straightforward than once thought. ZEUS, a global phase 3 clinical trial led by Mass…